Statera Biopharma, Inc. (STAB)
| Market Cap | 42.85K |
| Revenue (ttm) | 3.69M |
| Net Income (ttm) | -95.43M |
| Shares Out | 71.42M |
| EPS (ttm) | -2.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,265 |
| Open | 0.0006 |
| Previous Close | 0.0006 |
| Day's Range | 0.0006 - 0.0006 |
| 52-Week Range | 0.0001 - 0.0380 |
| Beta | 281.36 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 5, 2023 |
About STAB
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical pro... [Read more]
Financial Performance
Financial StatementsNews
Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs
FORT COLLINS, Colo., March 15, 2023 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (OTCPK:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapi...
Statera Biopharma Announces Completion of Application Process to Uplist to the OTCQB(R) Venture Marketplace
FORT COLLINS, CO / ACCESSWIRE / January 24, 2023 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies t...
Statera Biopharma Receives Positive Nasdaq Listing Determination
FORT COLLINS, CO / ACCESSWIRE / October 27, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies t...
Statera Biopharma Files Form 10-Q and Reaches Agreement with Silverback Capital and AVOF
FORT COLLINS, CO / ACCESSWIRE / October 21, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies t...
Statera Biopharma Announces Signing of a Binding MOU with Holobeam Technologies to Gain Access to Holobeam's Disruptive Diagnostic Imaging and Therapeutic Technology for Cancer Patients
FORT COLLINS, CO / ACCESSWIRE / October 17, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies t...
Statera Biopharma Completes Fiscal 2021 Audit; Files Form 10-K
FORT COLLINS, CO / ACCESSWIRE / October 6, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies th...
Statera Biopharma Receives Nasdaq Listing Determination; Hearing Requested to Address Filing Delinquency
FORT COLLINS, CO / ACCESSWIRE / September 9, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies ...
Statera Biopharma Receives Anticipated Notice of Additional Filing Delinquency from Nasdaq
FORT COLLINS, CO / ACCESSWIRE / August 25, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies th...
Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm
FORT COLLINS, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune therap...
Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing
FORT COLLINS, Colo., May 23, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune resto...
Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products
Statera expects to acquire option to license Lay Sciences products for respiratory & gastrointestinal disorders Statera expects to acquire option to license Lay Sciences products for respiratory & gas...
Why Are Statera Biopharma Shares Surging Today
Statera Biopharma Inc (NASDAQ: STAB) has entered into a non-binding term sheet with Immune Therapeutics Inc (OTC: IMUN) to sell its naltrexone and met-enkephalin rights. The transaction is contingent ...
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone
FORT COLLINS, Colo., April 27, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a leading biopharmaceutical company creating next-generation immune therapies that focus on im...
Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing
FORT COLLINS, Colo., April 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune res...
Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod
FORT COLLINS, Colo., April 13, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune res...
Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma
Entolimod is currently in clinical development as a potential treatment for acute radiation syndrome with additional preclinical programs advancing in neutropenia and anemia in cancer patients WEXFORD...
Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022
Live Conference Call and Webcast at 5:30 p.m. ET
Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering
FORT COLLINS, Colo., March 24, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immu...
Statera Biopharma Announces Pricing of $5.7 Million Underwritten Public Offering
FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immu...
CORRECTION -- Statera Biopharma Announces Proposed Underwritten Public Offering
FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immu...
Statera Biopharma Announces Proposed Underwritten Public Offering
FORT COLLINS, Colo., March 21, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immu...
Statera Biopharma Announces Revised Preliminary Revenue and Financial Results of Fiscal Year 2021
FORT COLLINS, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immu...
Statera Biopharma Advances Next-Gen Proprietary Compositions Based on STAT-200 Platform
In collaboration with MolSoft, ImQuest, a Statera company, is investigating new, optimized compositions incorporating desirable elements of STAT-200
CORRECTION - Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19
Statera developing STAT-205 as novel therapy for immune modulation in treating post-acute (long-haul) patients with SARS-CoV-2 (COVID-19) Statera developing STAT-205 as novel therapy for immune modula...
Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19
Statera developing STAT-205 as novel therapy for immune modulation in treating post-acute (long-haul) patients with SARS-CoV-2 (COVID-19) Statera developing STAT-205 as novel therapy for immune modula...